Payer Marketing as a Growth Lever: How Top Brands Are Investing

Why the most strategic life sciences brands are treating payer marketing as core commercial strategy, and where the smartest investment is happening now.

The Data Behind the Shift

Fewer than 10% of global pharmaceutical launches achieve true excellence, according to IQVIA analysis. The brands that miss that mark rarely fail because of weak science. They fail because the access story did not arrive on time, in the right format, for the right audience.

That is the expensive part most brand teams underestimate.

Pharma companies spend roughly a quarter of their net sales on commercial activity, with most large companies investing more in marketing than in research and development. The portion of that spend directed at payer audiences has historically been smaller than its strategic weight warrants. That math is changing fast. The brands now outpacing their categories are treating payer marketing as a growth lever, not a launch checkbox.

 

The Reframe: From Nice-to-Have to Commercial Backbone

For two decades, the dominant launch playbook treated payer engagement as a parallel track. Brand built the campaign. Medical built the data. Access built the dossier. Three teams, three timelines, one product trying to enter the market with three different stories.

That model no longer fits the market.

The U.S. is now operating in what IntegriChain analysts call a multi-payer, multi-pricing, multi-channel era. Five distinct payer types now define commercial strategy: commercial concierge, commercial, Medicare, Medicaid, and self-pay. Each requires its own evidence story, its own value framing, and its own engagement cadence. A single value dossier built in the final months before launch cannot serve all five at once.

The brands building forward are restructuring how payer marketing fits into commercial planning. Payer marketing is becoming the strategy layer that holds the others together.

Where the Smart Investment Is Going

Across pharma, biotech, medtech, and medical device, the leaders are concentrating investment in four areas. None of them are new. What is new is the level of capability inside each area and the integration across them.

1. Payer-Specific Value Propositions

The era of one master value story is closing. Brands gaining ground are building modular value architectures: a core proposition that compresses cleanly into four to six minutes of payer attention, with dedicated overlays for commercial, government, and integrated delivery network audiences.

What looks like a tactical adjustment is a strategic move. A brand cannot win a Medicare conversation with a story built for a commercial PBM. The teams gaining ground are designing value at the architecture layer, then customizing the expression for each audience.

2. Health Economics and Outcomes Capabilities

Real-world evidence has moved from validation tool to commercial differentiator. Guidehouse’s 2026 commercialization outlook flagged RWE as essential to category leadership, and IQVIA launch research shows the leading brands are now generating real-world insights as a continuous stream, not a one-time deliverable.

The investment is two-sided. Data infrastructure on the back end. Translation expertise on the front. A 200-page HEOR study only matters if a payer can see the story inside it within their decision window.

3. Digital Payer Engagement

Payer-side decision makers are now consuming brand-side content the way HCPs do: digitally, asynchronously, and on their schedule. The brands investing here are building secure portals, on-demand evidence libraries, and clinically rigorous interactive tools that put control of the discovery process in the payer’s hands.

This is the area most life sciences brands have under-invested in to date. It is also where the gap between leaders and laggards is widening fastest.

4. Partnership Models

Outcomes-based contracts (OBCs) are no longer the experimental edge. According to Simon-Kucher analysis, more than 58% of U.S. payers had at least one outcomes-based contract in place by 2022, and adoption has climbed since. Brands are investing in the infrastructure to participate: data systems that track outcomes in near real time, contract design expertise, and the cross-functional muscle to negotiate them.

The brands without OBC capability are working against a clock that started ticking when the 58% threshold passed.

The Payer Marketing Maturity Model

Most brand teams already know intuitively where they sit. Naming it builds the case for investment. Below is the four-stage model XCH uses with clients to ground that conversation.

Stage One: Launch-Centric

Payer engagement begins after the brand strategy is set. The value dossier is built in the final months before launch. There is no RWE plan beyond pivotal trial data. The payer team operates separately from brand and medical.

Common signal: The first time the brand team and the payer team meet about messaging is six months before launch.

Stage Two: Access-Aware

Payer marketing is integrated into launch planning, but follows brand. HEOR data is generated, though rarely re-translated for non-clinical payer audiences. Some pre-launch payer engagement happens, mostly through medical affairs.

Common signal: Payer materials exist, but they look like clinical materials with a dollar figure attached.

Stage Three: Value-Forward

Pre-Approval Information Exchange (PIE) is in active use, allowing scientific and economic information to flow to payers 6 to 18 months before FDA approval. Value architecture is modular by audience. RWE is generated as a continuous stream. Payer marketing has its own creative and content discipline.

Common signal: The brand team can describe the payer story in two minutes, in plain language.

Stage Four: Partnership-Native

Outcomes-based contracting capability is in place. Digital payer engagement runs on a dedicated platform. Real-time evidence flow informs commercial decisions across the lifecycle. Payer, medical, brand, and HEOR teams operate as one commercial unit.

Common signal: The CFO can describe the payer marketing strategy as cleanly as the sales strategy.

 

Three Actions for the Next 30 Days

A maturity model is useful only if it points toward the next move. For brand marketers ready to advance their payer marketing position, three actions will produce more value than any of them in isolation.

1. Run a six-minute test on your current payer narrative. Take your most recent value dossier or AM deck. Hand it to a colleague unfamiliar with the brand and ask them to describe the value proposition after six minutes. If they cannot, neither can a payer. That gap is your starting point.

2. Map your evidence story against the four investment areas. Pull your value architecture, your HEOR plan, your digital payer presence, and your contracting strategy onto one page. Where the page is blank, that is where leaders are investing. The exercise reveals the shape of the gap, and the shape of the gap is your strategy roadmap.

3. Schedule a cross-functional payer strategy session. Bring brand, market access, medical, and HEOR into one room within the next thirty days. The single biggest predictor of payer marketing maturity is whether these four functions plan together or hand off in sequence. If your team has not had this conversation in the past quarter, that is the conversation to have first.

A Consultative Close

Xavier Creative House (XCH) has spent more than 13 years inside life sciences, working with brand and access teams across pharma, biotech, and medtech. We have watched the brands that treat payer marketing as a strategic backbone outpace the ones that treat it as a launch deliverable. The investment patterns differ. The mindset differs more.

The brands building toward Stage Four build the capability now, before the launch trigger ever fires. By the time the access conversation begins externally, it has already been in motion internally for months.

If your team is sitting with the question of where to invest next, we would welcome a candid conversation about what we are seeing across the category and where the highest-impact moves sit for your specific situation. The right starting point depends on where you sit on the maturity model, what your launch window looks like, and how your access function is structured today.

We are happy to talk through any of it.